|
|
| Gene : |
IL1B |
| Gene ID : |
3553 |
| Uniprot ID : |
P01584 |
| Alternative Name : |
Interleukin-1 beta, Catabolin |
| Format : |
Purified |
| Amount : |
100 μg |
Target: IL-1 Beta
Generic name: Canakinumab
Product Origin: Recombinant in CHO cells
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass with a molecular mass of 145157 Daltons when deglycosylated. Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra).
References:
1. Church LD, McDermott MF: Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009 Feb;11(1):81-89.
2. Lachmann HJ, et al.: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009 Jun 4;360(23):2416-25. doi: 10.1056/NEJMoa0810787
Specificity: Human IL1 beta. Does not cross react with other members of the interleukin-1 family.
Inquire for more than 1 mg quantities.
Availability 5-7 weeks.
